City of Hope in the News
THIS KIND OF DIET MAY LOWER THE RISK OF DYING FROM BREAST CANCER [FULL ARTICLE]
- In anew study published inJAMA Oncology, researchers found diet may lower the risk of dying from cancer. Lead author Rowan T. Chlebowski, M.D., Ph.D.,research professor, Department of Medical Oncology & Therapeutics Research at City of Hope, and his colleagues analyzed data from more than 48,000 women. All of the women were cancer-free at the start of the study, and nearly 20,000 were randomly assigned to change their diet and lower their fat intake to about 20 percent of their daily calories.
- After 8.5 years of follow up, researchers found that among the women diagnosed with breast cancer, those in the low-fat diet group lowered their risk of dying from the disease by 22 percent, compared to women in the regular diet group.
- “What we see is a pretty remarkable effect,” said Chlebowski. “What we’ve shown is that it looks like dietary intervention after diagnosis [of breast cancer] was more important than dietary intervention before diagnosis.”
- Chlebowski is continuing studies to see if he and his colleagues can isolate the processes that tie diet to improved cancer survival, and investigate whether these can be turned into treatments that can increase people’s chances of surviving diseases like breast cancer.
10 SUPERHERO NURSES MAKING A BIG DIFFERENCE – WALKING THE WALK: PAMELA MCTAGUE [FULL ARTICLE]
O, The Oprah Magazine
- Pamela McTague, R.N., clinical research nurse at City of Hope, was featured in O, The Oprah Magazine’s May issue as one of 10 nurse superheroes.
- In her position, McTague meets patients after their diagnosis and shepherds them through clinical trials, explaining processes and procedures, like radioactive-isotope injections and monitoring their prognosis. Beyond her role at City of Hope, McTague maintains ongoing relationships with her patients, checking in at three months, six months, a year, even five years.
- But what really makes McTague a “superhero nurse” is her perspective and hope as a breast cancer survivor herself. She was diagnosed with cancer in both breasts in October 2016, then had a lumpectomy, radiation and plastic surgery.
- McTague credits her cancer with making her better able to prepare patients for the aftermath of treatment.
OPTING FOR HOPE [LINK N/A]
Orange County Business Journal
- As of June 9, Annette Walker, former president of strategy at Providence St. Joseph Health, ended her role at the Washington-based health system to take on the presidency of City of Hope, Orange County.
- The $200 million cancer center will be built in the Great Park Neighborhoods in Irvine, Orange County, on a 1,300-acre, mixed-use project of FivePoint Holdings. FivePoint is donating the land for the 70,000-square-foot cancer center.
- The center will house leading-edge technology –“radiation, advanced imaging diagnostics, a women’s center, and infusion and supportive services, including genetic counseling,” said Robert W. Stone, president and chief executive officer at City of Hope. “It will also offer preventive education, including wellness and nutrition advice, which aim to impact lives before they are even diagnosed with cancer.”
- In Walker’s new position, she will have full control in driving the development of City of Hope, Orange County. “This is not a role I went out and advertised for and looked at multiple people –I designed the role for Annette Walker,” said Stone.
- “City of Hope’s mission called to me to extend my personal mission to the community I call home,” said Walker.
- Additional coverage appeared in five articles, including a print Los Angeles Business article and Modern Healthcare.
BONE MARROW TRANSPLANT REUNION [FULL ARTICLE]
NBC 4 News Los Angeles
- On May 11, two cancer survivors and City of Hope patients met, for the first time, the bone marrow donors who saved their lives.
- In 2015, when Arturo Martinez was 11 years old, he was diagnosed with acute lymphoblastic leukemia and needed a transplant. Nick Martinez (no relation), then 27, had signed up for the bone marrow registry after encouragement from a friend whose relative had died of leukemia. Thanks to Nick’s donation, Arturo received a bone marrow transplant in 2012.
- In 2012, Gary Stromberg, father of two and co-founder of GIBSON & STROMBERG, a large and influential music public relations firm, was diagnosed with acute myeloid leukemia. Only a couple months after his diagnosis, he received his lifesaving bone marrow transplant from Alex Kikas,a Russian native who immigrated to Israel.
- Today, both Arturo and Gary are cancer-free thanks to their bone marrow donors.
- There were eight additional stories on the BMT Reunion, including ABC 7 Los Angeles and Univision.
COULD A VACCINE BE THE END OF TYPE 1 DIABETES? [FULL ARTICLE]
Los Angeles Magazine
Los Angeles Magazine
- The Los Angeles Magazine Top Doctors column featured Bart O. Roep, Ph.D., Wanek Family Project Director, professor and founding chair, Department of Diabetes Immunology, Chan Soon-Shiong Shapiro Distinguished Chair in Diabetes at City of Hope.
- Determined to improve the odds for people living with diabetes, Roep left the Netherlands to join City of Hope in 2016 and now leads the Wanek Family Project for Type 1 Diabetes with the goal of curing type 1 diabetes in six years. City of Hope supports Roep’s goal and research with a $50 million grant from the Wanek Family and anonymous donors.
- About 1.5 million Americans are affected by type 1 diabetes, and the search for its cause has turned up many possible hereditary and environmental factors.
- Roep and his team are now working on a solution: a diabetes vaccine. A trial to assess safety and tolerance looks promising in the Netherlands, and the vaccine’s effect on blood sugar regulation will be tested on City of Hope patients this year.
- “We teach immune cells to suppress their response,” Roep explained.
THE CROWD: CITY OF HOPE EVENT SHARES CANCER SURVIVAL STORIES AND RAISES FUNDS [FULL ARTICLE]
Los Angeles Times
Los Angeles Times
- On April 7, City of Hope patients Frank DiBella and Donna Porter shared their cancer survival stories with more than 400 friends at the fourth annual Let's Be Frank About Cancer event at Balboa Bay Resort in Newport Beach.
- The event was created by DiBella, who was diagnosed with metastatic bladder cancer in 2011 and told by doctors at several different hospitals that he had months to live. Finally, DiBella ended up at City of Hope where he was treated by Sumanta Kumar Pal, M.D.,associate clinical professor, Department of Medical Oncology & Therapeutics Research, co-director, Kidney Cancer Program. Now, seven years later, Pal joins DiBella and friends at the event each year.
- Steven T. Rosen, M.D., provost and chief scientific officer, also attended this year’s event, which raised $1 million for City of Hope. The funds are earmarked for Pal's research into improved treatment and ultimately, a cure.
WILL YOU CHANGE HOW YOU TREAT LUNG CANCER? [FULL ARTICLE]
- Results from a group of metastatic nonsquamous cell non-small cell lung cancer (NSCLC) trials presented at the American Association for Cancer Research (AACR) Annual Meeting could have practice-changing implications.
- MedPage Today invited top specialists in oncology to discuss the data, including Karen Reckamp, M.D.,co-director, Lung Cancer and Thoracic Oncology Program at City of Hope, who shared her thoughts on use of tumor mutational burden (TMB).
- According to Reckamp, doctors perform next-generation sequencing (NGS) testing as a standard of care for lung cancer patients (and a TMB is reported with most NGSs), but do not currently use TMBs to plan treatment since the data is based on small subsets.
- Data presentations on studies using ipilimumab and nivolumab showed that new populations may benefit from immune checkpoint inhibition with TMB testing.
AGE-RELATED CHANGES IN BREAST TISSUE MIGHT INCREASE CANCER RISK [LINK UNAVAILABLE]
- Age-related changes in subsets of breast tissue might increase susceptibility to breast cancer, according to a study led by Mark A. LaBarge, Ph.D., professor, Department of Population Sciences at City of Hope.
- The findings, published in Cell Reports, may help scientists better understand how breast cells change during the aging process, enabling doctors to catch the signs of cancer earlier.
- Previous studies have shown that, as women age, the composition of their breast tissue changes and multipotent progenitors build up in the body.
- “We hypothesized that accumulation of those progenitors is one of the mechanisms that underlies increased susceptibility to breast cancer with age,” explained LaBarge. “We saw a glimpse of this in past data, but this is the first study to identify these age-related differences at such high resolution.”
CITY OF HOPE PROPOSING $200 MILLION CANCER CENTER IN IRVINE NEAR ORANGE COUNTY GREAT PARK [FULL ARTICLE]
Orange County Register
Orange County Register
- City of Hope is planning to build a $200 million cancer center, which would anchor a future medical campus south of the Orange County Great Park in Irvine.
- The new outpatient center would open on land donated by FivePoint, which is overseeing the development of about 10,000 homes around the Great Park. It would be City of Hope’s first Orange County location.
- Harlan Levine, M.D., president of strategy and business ventures at City of Hope, said the cancer center would be designed to accommodate up to 75,000 patient visits in a year, and provide services such as medical, surgical and radiation oncology, advanced diagnostic imaging and an infusion center.
- In the past five years, City of Hope has grown to 29 locations across Southern California.
- Additional coverage appeared in Orange County Business Journal, Connect Media and California Healthline Daily Edition.
CITY OF HOPE RESEARCHERS DEVELOPING BREAKTHROUGH LEUKEMIA TREATMENT [FULL ARTICLE]
ABC 7 Los Angeles
ABC 7 Los Angeles
- Guido Marcucci, M.D., chair and professor of the City of Hope Department of Hematologic Malignancies Translational Science, and director, Gehr Family Center for Leukemia Research at City of Hope, and Bin Zhang, Ph.D., associate research professor in the Department of Hematologic Malignancies Translational Science at City of Hope, are developing a treatment for chronic myelogenous leukemia (CML). The drug called miristen targets leukemia stem cells, and in animal studies, researchers found that combining it with a tyrosine-kinase inhibitor made cancer cells disappear.
- According to Marcucci, the treatment could potentially send CML into permanent remission. It would be taken as a pill that would keep the leukemia in check and allow people with CML to live a normal life.
- While it will take about one to two years to bring miristen to human clinical trials, Marcucci says the initial studies in the lab look very promising. City of Hope researchers believe this combined therapy could also treat other forms of leukemia, as well as other types of cancer.
HERE'S THE PROBLEM WITH TODAY'S HUMAN CLINICAL TRIALS [FULL ARTICLE]
- The cost to develop and gain approval for a new drug today is more than $2.5 billion, according to the Tufts Center for the Study of Drug Development. Driving much of the cost are human clinical trials — and yet, experts at the Fortune Brainstorm Health conference agreed there aren’t enough adult patients enrolling in them.
- Part of the issue is getting the right patient, which can be difficult, said Linda Malkas, Ph.D., the M.T. & B.A. Ahmadinia Professor in Molecular Oncology at City of Hope.
- Malkas also emphasized patients’ desire to participate in trials close to home. “We’re almost getting a two-tier system here —those that have access to a major medical center and those that do not.”
- Another problem facing trials is that researchers conduct a lot of studies that are not worth doing, explained Malkas. “There are too many people and organizations making minor adjustments and launching new trials instead of looking at the big picture. That’s not going to move the ball down the field,” she said.
- “You don’t need 100 trials,” she added. “You may get an answer in 10 if you do it carefully.”
WHY ALL COMMUNITIES SHOULD HAVE ACCESS TO QUALITY CANCER CARE [FULL ARTICLE]
Future of Personal Health
- In a byline, Michael A. Caligiuri, M.D., president, City of Hope National Medical Center, and the Deana and Steve Campbell Physician-in-Chief Distinguished Chair at City of Hope discussed the need for ways to ensure that all individuals, no matter their background, benefit from quality cancer care.
- There have been incredible advances in cancer research and treatment in recent years. However, cancer incidence and mortality still disproportionately affect certain communities within society, such as African-American men, who are more than twice as likely to die of prostate cancer compared to men of all other racial backgrounds.
- A major focus during Caligiuri’s term as president of the American Association for Cancer Research has been to facilitate progress to eliminate these cancer disparities through providing easy access to high quality care and genomic sequencing in underrepresented populations.
- Additional coverage appeared in MD Alert and Cure Today.
CAN GENE THERAPY BE HARNESSED TO FIGHT THE AIDS VIRUS? [FULL ARTICLE]
- Approximately 100 people living with HIV have been able to stay off AIDS/HIV drugs for a couple years thanks to an innovative gene-editing treatment.
- Now researchers think they can improve the treatment and try tackling HIV with genetically modified DNA. The gene editing tool, which is called zinc finger nucleases, can cut DNA at a precise spot to disable the HIV entryway gene.
- John A. Zaia, M.D., Aaron D. Miller and Edith Miller Chair in Gene Therapy, program director, City of Hope Alpha Clinic, is among researchers taking this approach to treating HIV. However, Zaia is testing the approach with a twist: He’s using blood stem cells. “Once a stem cell is altered, the benefit should multiply and last longer,” Zaia said.
- Additional coverage appeared in Daily Mail, The Washington Post, Business Insider, ABC News, STAT News, U.S. News & World Report, NY Daily News, SF Gate and Miami Herald. *An additional 174 articles are available upon request.
EARLY PROSTATE CANCER KEPT AT BAY IN TWO STUDIES FOR HIGH-RISK MEN [FULL ARTICLE]
- In two separate studies, Johnson & Johnson’s experimental drug apalutamide and Pfizer’s enzalutamide delayed progression of early-stage prostate cancer in patients who were at high risk of metastasis by more than 70 percent compared with a placebo.
- Johnson & Johnson’s study, called Spartan, showed men treated with apalutamidewent for 40 months, or 3.3 years, before the cancer metastasized, compared with 16 months in the placebo group. Additionally, men treated with Pfizer’s enzalutamidesurvived for a median of 36 months before the cancer spread, compared with 14.7 months for those given a placebo.
- “These patients can have a poor prognosis, and until now, the optimal management of their cancer remained an enigma,” said Sumanta Kumar Pal, M.D., associate clinical professor, Department of Medical Oncology & Therapeutics Research, co-director, Kidney Cancer Program at City of Hope, who reviewed the findings of both studies on behalf of the American Society of Clinical Oncology. “These findings suggest there may finally be a treatment that holds real promise for extending their health.”
STATE EARNS FIRST ROYALTY CHECK AFTER INVESTING BILLIONS IN STEM CELL RESEARCH [FULL ARTICLE]
San Francisco Chronicle
San Francisco Chronicle
- City of Hope has sent the first royalty check to the California state treasurer’s office related to research funded by the California Institute for Regenerative Medicine (CIRM).
- “I think this illustrates that a state agency can actually fund research in the private community and get a return on its investment,” said John A. Zaia, M.D.“It’s something that’s not done in general by other funding agencies such as the National Institutes of Health, and this is a proof of concept that it can work.”
- In 2012, City of Hope received a $5.2 million CIRM grant to research and develop genetically modified T cells to treat brain cancers. New York biopharmaceutical company Mustang Bio eventually licensed several inventions funded by the CIRM grant.
- “If [the treatment is] ultimately approved by the [U.S. Food and Drug Administration] as a commercial product, this could be a continued revenue source for California,” explained Christine Brown, Ph.D., Heritage Provider Network Professor in Immunotherapy, associate director, T Cell Therapeutics Research Laboratory at City of Hope.
- Additional coverage appeared ineight outlets, including Bloomberg, The New York Times and The Stem Cellar.
CHEN, BILD, KAHN, HEISTERKAMP JOIN CITY OF HOPE [FULL ARTICLE N/A]
The Cancer Letter
The Cancer Letter
- The Cancer Letter reported on four of City of Hope’s recent new hires.
- Jianjun Chen, Ph.D., professor and vice chair, Department of Systems Biology, a permanent member of the National Institutes of Health’s Developmental Therapeutics study section, joined from the University of Cincinnati College of Medicine.
- Andrea Bild, Ph.D., professor, Division of Molecular Pharmacology, Department of Medical Oncology & Therapeutics Research, joined from the University of Utah, where she focused on systems biology and genomic characterization of cancer tumors to prevent resistance and progression.
- Michael Kahn, Ph.D., professor and associate chair, Department of Molecular Medicine, andNora Heisterkamp, Ph.D., professor, Department of Systems Biology, both joined from University of Southern California. Kahn’s research focused on the integration of basic science and translational medicine. Heisterkamp uncovered the Philadelphia chromosome’s structure.
ROSE PARADE COUNTDOWN [FULL ARTICLE]
KTLA 5 Los Angeles
KTLA 5 Los Angeles
- Before the start of this year’s Rose Parade, KTLA 5 Los Angeles interviewed Los Angeles Dodger Enrique “Kiké” Hernández along with his father Enrique Hernández Sr., former Los Angeles Dodgers general manager Fred Claire and Stephen J. Forman, M.D., Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, director, T Cell Therapeutics Research Laboratory at City of Hope.
- During the segment, Claire discussed his experiences at City of Hope and thanked his team of doctors and nurses.
- “I know a little bit about championship teams and I tell you, City of Hope has a championship team,” said Claire, who rode atop City of Hope’s 2018 Rose Parade float, which won the Isabella Coleman award for its outstanding presentation. “I think any of us who have had the opportunity to see what's done at City of Hope can't help but be impacted.”
- Thanks to the team at City of Hope, Hernández Sr. and Claire are now cancer-free.
- There were more than 100 articles on City of Hope’s Rose Parade float, including NBC News, Los Angeles Times, Dodger Nation, Los Angeles Daily News, NBC 4 Los Angeles, Pasadena Star-News, and Southern California Public Radio.
ARE WOMEN MORE SUSCEPTIBLE TO LUNG CANCER THAN MEN? [FULL ARTICLE]
U.S. News & World Report
- Today, lung cancer is the deadliest cancer among women – killing more women than breast cancer, uterine cancer and ovarian cancer combined. While the incidence rate of lung cancer has dropped among men over the past few decades, it has risen among women.
- “There are multiple theories, but no definitive answer [for what’s driving these rates and why there is a sex difference in lung cancer],” said Karen Reckamp, M.D., M.S., co-director, Lung Cancer and Thoracic Oncology Program at City of Hope.
- Reckamp explained that hormones could be a contributing factor, as some studies have shown that certain forms of lung cancer feed on estrogen, and some studies have shown a potential link between hormone replacement therapy and a worse outcome for women with lung cancer.
- Additionally, Reckamp said environmental and genetic aspects may contribute. Researchers are currently conducting studies investigating the genetics of lung cancer in hopes of developing a lung cancer screening.
BEYOND THE HEART – THE DR. NIECA GOLDBERG SHOW [FULL ARTICLE N/A]
Sirius XM Doctor Radio
Sirius XM Doctor Radio
- On Jan. 26, Fouad R. Kandeel, M.D., Ph.D., director, Islet Cell Transplantation Program at City of Hope, and City of Hope patient Beth Jenkins, M.D., participated in a one-hour Sirius XM Doctor Radio segment and discussed ongoing diabetes research and the islet transplantation clinical trial program that Jenkins participated in at City of Hope.
- Before Jenkins, a 43-year old mother, pediatrician and type 1 diabetic, enrolled in City of Hope’s clinical trial in 2009, she had been experiencing hypoglycemic unawareness for several years, which made her unexpectedly pass out and even caused her to go into a coma a few times.
- Thanks to the islet cell transplant clinical trial at City of Hope, Jenkins is now insulin-free and the first patient in the U.S. (and second in the world) to have had a successful pregnancy post-transplant.
- During the segment, Kandeel and Jenkins also discussed the various diabetes research projects underway at City of Hope as part of the Wanek Family Project for Type 1 Diabetes, including immune modulation, beta cell expansion and the development of a type 1 diabetes vaccine.
A PERSONAL ATTACK: FAMILY ROOTS OF PROSTATE CANCER [FULL ARTICLE]
- The sidebar of Genome’s cover story featured commentary by Rick Kittles, Ph.D., professor and founding director, Division of Health Equities, Department of Population Sciences at City of Hope, on research that aims to identify why prostate tumors in African-American men have a higher rate of mutations in key genes.
- Changes in the LSAMP gene happen more frequently in African-American men with prostate cancer. Variants in this gene are also associated with an increased risk of recurrence after surgery in African-American men.
- “There is a strong genetic component. We need to find out what’s going on,” explained Kittles. However, Kittles said there is a downside to combining race and genetics.
- “I’m a geneticist, but I am also a black male, and so there is cause for concern, particularly for groups that have been marginalized and stigmatized,” he said. “As scientists, we have to be responsible and show a level of sensitivity and understanding about what we are saying about our results and our data.”
COULD GENE THERAPY BE THE NEWEST CANCER TREATMENT? [FULL ARTICLE]
Southern California Public Radio
Southern California Public Radio
- Stephen Forman, M.D., F.A.C.P., Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation at City of Hope, was a guest on Southern California Public Radio’s “AirTalk” show and discussed new CAR T therapies up for review by the U.S. Food and Drug Administration for the treatment of blood cancers.
- Forman provided background on what CAR T therapy is and how it works. He also discussed the risks involved and the challenges doctors are facing when tailoring this treatment to solid tumors, such as the glioblastoma that Sen. John McCain was recently diagnosed with.
- During the show, Forman mentioned City of Hope’s CAR T cell clinical trial that evaluated the effects of injecting re-engineered cells directly into a glioblastoma patient’s brain.
- Similar coverage appeared on KTLA 5 Los Angeles featuring neurosurgeon and scientist Rahul Jandial, M.D., Ph.D., associate professor, Division of Neurosurgery, Department of Surgery at City of Hope, and STAT News featuring Christine Brown, Ph.D., Heritage Provider Network Professor in Immunotherapy, associate director, T cell Therapeutics Research Laboratory at City of Hope.
NEW FORM OF THERAPY TREATS SEN. MCCAIN'S TYPE OF CANCER [FULL ARTICLE]
FOX & Friends
FOX & Friends
- Lindsay Rosenwald, M.D., chairman and CEO of Fortress Biotech, and Manuel Lichtman, M.D., president of Fortress subsidiary Mustang Bio, were guests on FOX & Friends to discuss Sen. John McCain’s recent glioblastoma diagnosis and advancements that Stephen Forman, M.D., F.A.C.P., Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, Christine Brown, Ph.D., Heritage Provider Network Professor in Immunotherapy, associate director, T cell Therapeutics, and Behnam Badie, M.D., F.A.C.S., chief of neurosurgery, vice chair and professor, Department of Surgery at City of Hope, are making in the field.
- Rosenwald mentioned City of Hope’s study using Mustang’s licensed CAR T cell therapy, noting that researchers injected the treatment directly into the brain of a glioblastoma patient – the first time CAR T has been used this way – and observed regression in the patient’s brain and spinal tumors.
- Similar coverage appeared in Daily Mail, as well as coverage featuring Badie and Brown in Los Angeles Times, The Sacramento Bee, and The California Stem Cell Report.
NOVARTIS CAR T CANCER THERAPY WINS EXPERT SUPPORT FOR FDA APPROVAL [FULL ARTICLE]
- A panel of experts convened by the U.S. Food and Drug Administration (FDA) voted 10-0 on July 12 to recommend the approval of Novartis’ CAR T therapy CTL019 for the treatment of children and young adults with advanced leukemia. The FDA is expected to make a final decision on approval by Oct. 3.
- CTL019 is the first CAR T therapy to come before the FDA, leading a group of novel treatments that promise to change the standard of care for some aggressive blood cancers.
- The panel discussed the treatment’s associated risks, including potential for deadly viral infections and brain toxicity, but noted that none of the risks should hinder an FDA approval. “I don’t think any of these considerations would be show-stoppers for the outstanding clinical results that have been obtained to date,” said Larry Kwak, M.D., Ph.D., director, Toni Stephenson Lymphoma Center at City of Hope.
- The FDA is also reviewing Kite Pharma’s CAR T therapy for the treatment of adults with advanced or aggressive lymphoma. An approval decision for the Kite CAR T therapy is expected on Nov. 29.
- Similar coverage appeared in Medscape featuring comments by Elizabeth Budde, M.D., Ph.D., assistant professor, Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, as well as in FierceBiotech and Nature Blogs.
SURGERY FOR EARLY-STAGE PROSTATE CANCER DOES NOT LEAD TO LONGER LIVES, STUDY FINDS [FULL ARTICLE]
Los Angeles Times
Los Angeles Times
- A study published in the New England Journal of Medicine found that men diagnosed with early-stage prostate cancer who forgo immediate surgery have the same odds of living another decade or two as patients who have their tumors surgically removed.
- Sumanta Pal, M.D., associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program at City of Hope, who was featured for his comments on the study, said the results are in line with the way doctors currently treat prostate cancer.
- Men with low-risk prostate cancer typically don’t die from the disease, so observation is usually sufficient.
- Additional coverage appeared in The Baltimore Sun and Orlando Sentinel. Similar coverage appeared in HealthDay, U.S. News & World Report, Philly.com and UPI.com.